Aging Demographics And Genetic Advances Will Unlock Neurological Breakthroughs

Published
11 Apr 25
Updated
06 Aug 25
AnalystHighTarget's Fair Value
US$249.66
45.9% undervalued intrinsic discount
06 Aug
US$135.19
Loading
1Y
-33.0%
7D
5.8%

Author's Valuation

US$249.7

45.9% undervalued intrinsic discount

AnalystHighTarget Fair Value

Shared on07 May 25
Fair value Decreased 12%

Shared on30 Apr 25
Fair value Decreased 6.36%

AnalystHighTarget has decreased revenue growth from 1.5% to 0.8%.

Shared on23 Apr 25
Fair value Increased 20%

AnalystHighTarget has increased future PE multiple from 15.0x to 18.0x.

Shared on16 Apr 25
Fair value Decreased 0.091%

AnalystHighTarget has increased revenue growth from 0.8% to 1.5%.